refractive surgery
Conditions
Interventions
experimental group 1:3% diquafosol was administered six times a day
experimental group 2:3% diquafosol was administered four times a day
Sponsors
Tianjin medical university eye hospital
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Preoperative diopter was between -3.0d to -6.0d and cylindrical diopter less than or equal to -3.00 D; 2. Study eye were eligible for FS-LASIK; 3. Patients who underwent bilateral FS-LASIK treatment; 4. Mild to moderate dry eye 1 week after FS-LASIK(Mild to moderate dry eye: The slit lamp examination for ocular surface injury does not exceed two quadrants; Cornea Fluorescein Staining from 2 to 30 seconds).
Exclusion criteria
Exclusion criteria: 1. Patients who have allergy history or adverse reactions to the experimental drugs or its components; 2. Patients with history of a primary condition that could cause dry eye, such as a pterygium, dellen and systemic connective tissue disease; 3. Patients with active ocular disease, uncontrolled systemic disease, history of ocular allergic disease, prior refractive surgery, ocular surgery or prior use of immune modulating agents; 4. Use 3% diquafosol for dry eye within 2 weeks before screening; 5. Patients who had involved in any other clinical trials within 3 months before screening; 6. Patients who are intolerant to combined pharmacotherapy in the trial; 7. Pregnant and lactating women, or those planning a pregnancy over the course of the study; 8. Patients judged by the investigator to be unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tear breakup time; | — |
Countries
China
Contacts
Public ContactZhao Shaozhen
Tianjin medical university eye hospital
Outcome results
None listed